Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02513472
Title Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eisai Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Facility #1 Duarte California 91010 United States Details
Facility #1 Santa Barbara California 93105 United States Details
Facility #1 Denver Colorado 80218 United States Details
Facility #1 Miami Florida 33176 United States Details
Facility #1 West Palm Beach Florida 33401 United States Details
Facility #1 Boston Massachusetts 02115 United States Details
Facility #2 Boston Massachusetts 02115 United States Details
Facility #1 Minneapolis Minnesota 55407 United States Details
Facility #1 Saint Louis Missouri 63110 United States Details
Facility #1 Lebanon New Hampshire 03756 United States Details
Facility #1 New York New York 10032 United States Details
Facility #2 New York New York 10065 United States Details
Facility #1 Chattanooga Tennessee 37404 United States Details
Facility #1 Nashville Tennessee 37203 United States Details
Facility #1 Austin Texas 78731 United States Details
Facility #1 Fort Worth Texas 76104 United States Details
Facility #1 San Antonio Texas 78217 United States Details
Facility #2 San Antonio Texas 78229 United States Details
Facility #1 Sherman Texas 75090 United States Details
Facility #1 Salem Virginia 24153 United States Details
Facility #1 Winchester Virginia 22601 United States Details
Facility #1 Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field